Want to see SXTP full AI Analyst Report?
SXTP Stock Chart & Stats
$0.50
-$0.08(-5.71%)
At close: 4:00 PM EST
$0.50
-$0.08(-5.71%)
Day’s Range― - ―
52-Week Range$1.22 - $10.77
Previous CloseN/A
Volume13.44M
Average Volume (3M)199.18K
Market Cap
$4.55M
Enterprise Value-$1.88M
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$151.97K
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Aug 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.41
Enterprise Value/Revenue-1.87
Enterprise Value/Gross Profit-8.95
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$3.70Price Target Upside640.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Positive EquityA low-debt balance sheet with positive equity (~$4.7M) reduces short-term solvency risk and gives management flexibility to prioritize development decisions. Over a 2–6 month horizon this structural strength lowers bankruptcy risk and supports funding options for clinical programs.
Clear Regulatory Strategy For TafenoquineA defined path toward an NDA and a Priority Review Voucher strategy provides a structural regulatory roadmap. If clinical data are favorable this can materially accelerate approval timelines and commercial entry, improving the company's long-term commercialization prospects.
DSMB Continuation For Babesiosis TrialAn independent DSMB recommending continuation reduces the operational risk of trial termination and affirms an acceptable safety profile to date. This preserves the trial timeline and supports the integrity of pivotal data needed for regulatory submissions and future labeling.
Bears Say
High Cash BurnSustained negative operating and free cash flow of ~-$8M TTM is a structural threat to runway. Absent near-term revenue inflection or financing, persistent cash burn forces dilution or spending cuts, constraining R&D and commercialization capacity over the medium term.
Very Small, Declining Revenue BaseA modest revenue base (~$1M TTM) declining ~14.5% indicates the company lacks commercial scale. Structural revenue weakness limits ability to cover fixed costs, making profitability and self-funding of trials unlikely without successful new product approvals or material market uptake.
Equity Financing / Dilution Risk (ATM Clarity)Legal clarity around the ATM confirms a near-term financing lever but signals potential dilution if used. Over 2–6 months this structural financing option can erode existing ownership, pressure per-share economics, and reflect dependency on external capital to fund operations and trials.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.22 and its highest was $10.77 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $4.55M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 47 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.74.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 2,659,288 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
SXTP Stock 12 Month Forecast
Average Price Target
$3.70
▲(640.00% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
0.33% Mutual Funds
5.44% Other Institutional Investors
93.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---